Bio-Techne
Preço: 54.00Empresa e modelo de negócios
Bio-Techne Corporation operates in the healthcare sector, specializing in the development and manufacturing of biotechnology products and tools. Its core offerings include proteins, antibodies, and reagents used in research and clinical applications. Major business segments consist of Protein Sciences, Diagnostics, and Clinical Diagnostics, with primary revenue sources stemming from sales of research reagents and instruments. The company serves academic, pharmaceutical, and biotechnology markets.
Perfil de investimento
The investment profile of Bio-Techne is more aligned with balanced investors, given its moderate growth potential and dividend yield. The stock exhibits characteristics suitable for those seeking a mix of capital appreciation and income, though it carries a higher risk profile. Investors may consider a medium to long-term horizon for potential returns, while liquidity remains moderate.
Métricas fundamentais (experimental)
- EPS (TTM) — lucro por ação dos últimos 12 meses, $
- 0.71 OK
- Receita QoQ — crescimento da receita trimestre contra trimestre
- 5.3% ↑
- Surpresa de EPS
- -3.6% em linha
- Volatilidade 20d
- 2.8% estável
- Dividend yield
- 0.6% baixo última data ex-dividendo: 2026-05-18
Acompanhar no portfólio
Gráfico de preço
| Data | Antes | Depois | Motivo |
|---|---|---|---|
| 2026-06-05 02:49 | Vender | Manter | Mixed performance; cautious outlook due to volatility. |
| 2026-05-30 02:52 | Manter | Vender | Weak fundamentals and negative momentum raise concerns. |
| 2026-05-08 15:11 | — | Manter | Weak fundamentals and negative momentum raise significant concerns. |
| Data | Analista | Action | Alvo | Preço na época |
|---|---|---|---|---|
| 2026-06-11 09:52 | Piper Sandler | Atualizar | — → 65 | 52.5 |
| 2026-05-14 20:21 | RBC Capital | Atualizar | — → 62 | 44.74 |
| 2026-05-07 12:07 | Evercore ISI | Preço-alvo reduzido | 54 → 50 | 49.265 |
Nada ainda